{"id":"cmf-chemotherapy","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Myelosuppression (neutropenia, anemia, thrombocytopenia)"},{"rate":"60-90","effect":"Nausea and vomiting"},{"rate":"20-40","effect":"Mucositis"},{"rate":"60-90","effect":"Alopecia"},{"rate":"50-80","effect":"Fatigue"},{"rate":"10-30","effect":"Diarrhea"},{"rate":"5-15","effect":"Cardiotoxicity (with cyclophosphamide)"},{"rate":"1-5","effect":"Secondary malignancy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CMF (Cyclophosphamide, Methotrexate, and Fluorouracil) is a polychemotherapy regimen where cyclophosphamide acts as an alkylating agent, methotrexate inhibits dihydrofolate reductase to disrupt nucleotide synthesis, and fluorouracil inhibits thymidylate synthase. Together, these agents target rapidly dividing cancer cells through multiple mechanisms of DNA damage and cell cycle disruption.","oneSentence":"CMF is a combination chemotherapy regimen that uses three cytotoxic agents to inhibit cancer cell division and induce apoptosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:30.097Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (adjuvant and metastatic settings)"}]},"trialDetails":[{"nctId":"NCT00036868","phase":"PHASE2","title":"Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2002-02","conditions":"Breast Cancer","enrollment":90},{"nctId":"NCT00433589","phase":"PHASE3","title":"Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2007-02","conditions":"Breast Cancer","enrollment":6600},{"nctId":"NCT04829890","phase":"","title":"Adjuvant Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer","status":"COMPLETED","sponsor":"Hellenic Cooperative Oncology Group","startDate":"2004-02","conditions":"Breast Cancer, Adenocarcinoma of Breast","enrollment":89},{"nctId":"NCT00309569","phase":"PHASE3","title":"Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients","status":"COMPLETED","sponsor":"Austrian Breast & Colorectal Cancer Study Group","startDate":"1991-10","conditions":"Early Stage Breast Cancer","enrollment":429},{"nctId":"NCT00002542","phase":"PHASE3","title":"Tamoxifen in Treating Women With High-Risk Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1993-07-20","conditions":"Breast Cancer","enrollment":672},{"nctId":"NCT01104935","phase":"PHASE3","title":"National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT]","status":"COMPLETED","sponsor":"Comprehensive Support Project for Oncology Research","startDate":"2009-10-28","conditions":"Breast Cancer","enrollment":275},{"nctId":"NCT02115204","phase":"PHASE3","title":"4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2000-06","conditions":"Breast Cancer","enrollment":2011},{"nctId":"NCT00301925","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery","status":"UNKNOWN","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2005-12-16","conditions":"Breast Cancer","enrollment":4400},{"nctId":"NCT01317108","phase":"PHASE3","title":"Prognostic and Predictive Impact of uPA/PAI-1","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"1993-06","conditions":"Breast Cancer","enrollment":689},{"nctId":"NCT00331097","phase":"PHASE3","title":"ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment","status":"COMPLETED","sponsor":"National Cancer Institute, Naples","startDate":"2003-07","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT00615901","phase":"NA","title":"Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-01","conditions":"Breast Cancer","enrollment":38},{"nctId":"NCT00066807","phase":"PHASE3","title":"Premenopausal Endocrine Responsive Chemotherapy Trial","status":"TERMINATED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-08","conditions":"Breast Cancer","enrollment":29},{"nctId":"NCT00024102","phase":"PHASE3","title":"Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2001-09","conditions":"Breast Cancer","enrollment":633},{"nctId":"NCT01530607","phase":"PHASE3","title":"Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer","status":"COMPLETED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2009-11","conditions":"Breast Cancer","enrollment":416},{"nctId":"NCT00544232","phase":"PHASE3","title":"Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2002-08","conditions":"Breast Cancer","enrollment":720},{"nctId":"NCT01204437","phase":"PHASE2, PHASE3","title":"Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2009-03","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT01998906","phase":"PHASE3","title":"A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-05","conditions":"Breast Cancer","enrollment":330},{"nctId":"NCT00012311","phase":"PHASE2","title":"Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer","status":"UNKNOWN","sponsor":"Herbert Irving Comprehensive Cancer Center","startDate":"2000-01","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00003577","phase":"PHASE3","title":"Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer","status":"COMPLETED","sponsor":"University Hospital Birmingham","startDate":"1996-03","conditions":"Breast Cancer","enrollment":2000},{"nctId":"NCT00003893","phase":"PHASE3","title":"Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer","status":"COMPLETED","sponsor":"University Hospital Birmingham","startDate":"1998-07","conditions":"Breast Cancer","enrollment":2250},{"nctId":"NCT00002498","phase":"PHASE2","title":"Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"1992-07","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00003680","phase":"PHASE3","title":"Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer","status":"UNKNOWN","sponsor":"Scottish Cancer Therapy Network","startDate":"1998-11","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT00002579","phase":"PHASE3","title":"Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer","status":"COMPLETED","sponsor":"Scottish Cancer Therapy Network","startDate":"1993-03","conditions":"Breast Cancer","enrollment":2000},{"nctId":"NCT00003012","phase":"PHASE3","title":"Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer","status":"COMPLETED","sponsor":"Scottish Cancer Therapy Network","startDate":"1996-10","conditions":"Breast Cancer","enrollment":1000},{"nctId":"NCT00002755","phase":"PHASE3","title":"Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"Scottish Cancer Therapy Network","startDate":"1995-11","conditions":"Breast Cancer","enrollment":600},{"nctId":"NCT00003013","phase":"PHASE3","title":"Chemotherapy Plus Surgery in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"1996-10","conditions":"Breast Cancer","enrollment":450},{"nctId":"NCT01554943","phase":"PHASE2","title":"Late Cardiac Evaluation of the Three Arm Belgian Trial Involving Node-positive Early Breast Cancer Patients","status":"COMPLETED","sponsor":"Jules Bordet Institute","startDate":"2010-07","conditions":"Breast Cancer","enrollment":73},{"nctId":"NCT00002696","phase":"PHASE3","title":"Combination Chemotherapy in Treating Women With Stage III Breast Cancer","status":"SUSPENDED","sponsor":"Grupo Oncologico Cooperativo del Sur","startDate":"1995-10","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00002582","phase":"PHASE3","title":"Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer","status":"COMPLETED","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"1993-06","conditions":"Breast Cancer","enrollment":6000},{"nctId":"NCT00002784","phase":"PHASE3","title":"High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"1996-06","conditions":"Breast Cancer","enrollment":344},{"nctId":"NCT00003953","phase":"PHASE2","title":"Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"1999-02","conditions":"Breast Cancer","enrollment":39},{"nctId":"NCT00003549","phase":"PHASE2","title":"S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1998-10","conditions":"Neuroendocrine Carcinoma of the Skin","enrollment":80},{"nctId":"NCT00033683","phase":"PHASE2","title":"Combination Chemotherapy in Treating Women With Resected Breast Cancer","status":"UNKNOWN","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2001-02","conditions":"Breast Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":194,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CMF Chemotherapy","genericName":"CMF Chemotherapy","companyName":"Universitätsklinikum Hamburg-Eppendorf","companyId":"universit-tsklinikum-hamburg-eppendorf","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CMF is a combination chemotherapy regimen that uses three cytotoxic agents to inhibit cancer cell division and induce apoptosis. Used for Breast cancer (adjuvant and metastatic settings).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}